Molecular Biology: Open
Access

11th International Conference on

**Antibiotics, Antimicrobials & Resistance** 

March 17-18, 2022 | London, UK

ISSN: 2168-9547

Volume 11 | ISSUE 01

Abstract (600 word limits)

Title: Characterization of adverse effects and it's associations in the patient medicated with antitubercular drugs

Priyatam Khadka<sup>1</sup>, Bhagwati Rai<sup>1</sup>,

Tribhuvan University Teaching Hospital, Kathmandu, Nepal

Abstract Background

Adverse effects from long-term therapeutic intervention in tuberculosis is obvious; however, were taken nonchalantly due to the only therapeutic alternative. The objective of this study was to characterize the adverse effects and it's associations in the patient medicated with antitubercular drugs.

Methods

A longitudinal prospective study was conducted among the patient medicated with antitubercular drugs. As per the guideline of Nepal's National tuberculosis control programme (NTP), Nepal, the treatment category was selected, fixed-dose-regimen was calculated, and treatment outcome was affirmed. Patients' demographics and other clinical details were extracted from the repository files. Upon a consecutive follow-up, observed adverse effects were noted and multivariate logistic analysis against independent factors was done for elucidating any association.

Result

Of 177 cases enrolled, 138(77.9%) reported at least two adverse effects. In our multivariate logistic analysis: female, abnormal body mass index (BMI) i.e. underweight and overweight cases, patients' behaviours i.e. smoking/drinking or both, clinical diagnosed cases and intensive treatment phase were independently associated with adverse side effects. Loss of appetite (85.4%) was the commonest while dermatologic manifestations (1.2%) and severe weight-loss (1.2%) were the least observed side-effects among the patient medicated with anti-

tubercular drugs. Absolute drug-induced-toxicity was observed in treatment failure or MDR (multi-drug-resistant) subjects.

## Conclusion

Adverse effects from anti-tubercular therapy are associated with patients' demographics variables. Symptomatic treatment, regular follow-up after implicated therapy, and therapeutic-discontinuation may be required for successful cases.

## Biography (200 word limit)

Priyatam khadka is a young, ebullient laboratory scientist; passionate on clinical microbiology, cell biology and cancer cell research; looking for a PhD. opportunity in the relevant topics of tropical and infectious disease, cancer cell and immune-therapy. Academically, he completed his Postgraduate in Medical Microbiology with a sound academic background. Currently, has been working as Medical Laboratory Professional in Tribhuvan University Teaching Hospital, Institute of Medicine, and Nepal for last 6 years and extra 3 yrs on other Health research institutes.

## References:

- 1) Chung-Delgado K, Revilla-Montag A, Guillen-Bravo S, et al. <u>Factors associated with anti-tuberculosis medication adverse effects: a case-control study in Lima, Peru</u>. *PLoS One*. 2011;6(11):e27610. doi:10.1371/journal.pone.0027610
- 2) Woimo, T.T., Yimer, W.K., Bati, T. et al. <u>The prevalence and factors associated for anti-tuberculosis treatment non-adherence among pulmonary tuberculosis patients in public health care facilities in South Ethiopia</u>: a cross-sectional study. *BMC Public Health* 17, 269 (2017) doi:10.1186/s12889-017-4188-9
- 3) Volmink J, Garner P: <u>Directly observed therapy for treating tuberculosis</u>. The Cochrane database <u>of systematic reviews</u> 2007;17(4):Cd003343.

Organization / University Logo

